FDA, Aetion Expand RWE Work To Focus On Inpatient COVID-19 Therapies

By Beth Wang / October 26, 2021 at 4:20 PM
FDA and Aetion announced they will use Aetion’s Evidence Platform to gather real-world evidence on inpatient COVID-19 therapies, with the goal of demonstrating how a platform-based approach can help advance regulatory knowledge on the use of RWE and also to provide a scalable infrastructure through which therapies for coronavirus and other future infectious diseases and pandemics can be rapidly developed and evaluated. FDA and Aetion’s contract will support the agency’s broader digital transformation efforts, which include its Technology and Data...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.